MLS-STAT3 Recombinant Peptide for Mitochondrial Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunosuppressants for autoimmune and inflammatory diseases are costly, have side effects, and require long clinical trials, while existing treatments targeting T cell activation pathways or cytokines are inefficient and expensive.
Innovation Solution
A recombinant peptide fusing mitochondria localization sequence (MLS) with signal transducer and activator of transcription 3 (STAT3) is developed to overexpress STAT3 in mitochondria, inhibiting inflammatory cytokines like IL-17, thereby regulating immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immunosuppressants (cyclosporine A and FK506) are used to treat autoimmune diseases, then immune response is suppressed, but treatment cost increases and side effects occur
Solution Approach 1:
The patent uses a short peptide sequence (aa 1-12 of STAT3) instead of complex long-acting immunosuppressants. This short peptide can be easily synthesized, is cost-effective, and achieves immune suppression through transient mitochondrial localization followed by degradation, eliminating the need for expensive, long-term administration of traditional immunosuppressants while reducing side effects
Solution Approach 2:
The patent extracts only the critical functional domain (aa 1-12) from the full STAT3 protein and fuses it with MLS. This extracted short peptide retains the essential immune regulatory function while removing unnecessary complexity, reducing manufacturing costs, and minimizing off-target effects associated with full-length protein therapy
2Duration of action of moving object
If immunosuppressants are administered long-term to regulate immune response, then disease symptoms are relieved, but disease recurrence frequency increases
Solution Approach 1:
The MLS-STAT3 peptide is designed for periodic administration rather than continuous treatment. After each dose, the peptide localizes to mitochondria, exerts its immune regulatory effect, and is then degraded. This periodic action pattern maintains immune balance over time while avoiding the cumulative toxicity and immune tolerance that lead to disease recurrence with long-term traditional immunosuppressant use
3Adaptability or versatility
If existing treatments targeting T cell activation pathways are used, then immune response is modulated, but treatment efficiency is low and cost is high
Solution Approach 1:
The patent uses mitochondrial STAT3 peptide as an intermediary that bridges mitochondrial function and immune regulation. Instead of directly targeting complex T cell activation pathways with multiple drugs, the MLS-STAT3 peptide acts as a simple mediator that localizes to mitochondria and indirectly modulates immune responses through mitochondrial-mediated mechanisms, achieving high efficiency with a single agent
Data Source
AI summary
The present invention relates to: a recombinant peptide in which a Mitochondria Localization Sequence (MLS) peptide and the Signal Transducer and Activator of Transcription 3 (STAT3) are fused to each other; a recombinant vector carrying a polynucleotide coding for the recombinant peptide; and a composition comprising the recombinant peptide or the recombinant vector as an active ingredient for prevention or treatment of autoimmune disease or inflammatory disease, wherein the recombinant peptide or the recombinant vector allows STAT3 to be overexpressed in the mitochondria to enhance the mitochondrial function, resulting in inhibiting the expression of inflammatory cytokines including IL-17, whereby the composition may be advantageously used for preventing or treating autoimmune disease or inflammatory diseases.